COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

PTG-300 in Subjects With Hereditary Hemochromatosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04202965
Recruitment Status : Recruiting
First Posted : December 18, 2019
Last Update Posted : December 18, 2019
Information provided by (Responsible Party):
Protagonist Therapeutics

Brief Summary:
This study will be conducted at multiple sites and every patient will get treated with PTG-300. The objective of the study is to assess the effect of PTG-300 in treating adult hereditary hemochromatosis patients.

Condition or disease Intervention/treatment Phase
Hereditary Hemochromatosis Drug: PTG-300 Phase 2

Detailed Description:
This study is a multicenter, open-label study. The objective of the study is to assess the effect of PTG-300 on transferrin saturation (TSAT) and serum iron in adult hereditary hemochromatosis patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 28 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Single Arm Study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-label Study of PTG-300 in Subjects With Hereditary Hemochromatosis
Estimated Study Start Date : January 2, 2020
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : June 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hemochromatosis

Arm Intervention/treatment
Experimental: PTG-300
PTG-300 Subcutaneous
Drug: PTG-300
Active treatment with PTG-300 subcutaneously

Primary Outcome Measures :
  1. Effect of PTG-300 on Transferrin Saturation [ Time Frame: Week 24 ]
    Change in transferrin saturation (TSAT) as measured by blood laboratory tests.

  2. Effect of PTG-300 on Serum Iron [ Time Frame: Week 24 ]
    Change in serum iron as measured by blood laboratory tests.

Secondary Outcome Measures :
  1. Effect of PTG-300 on Phlebotomy Frequency [ Time Frame: Week 24 ]
    Change in phlebotomy frequency as measured by number of phlebotomies over a 24 week period.

  2. SF-36 [ Time Frame: Week 24 ]
    The SF-36 is a participant-reported outcome measure. The instrument includes 36 items in a Likert-type format to measure the following health dimensions over the past week: limitations in physical activities; limitations in social activities; limitations in usual role activities; bodily pain; general mental health; vitality; and general health perceptions.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women aged 18 and older
  • Confirmed diagnosis of HFE-related hereditary hemochromatosis with prior genotype testing
  • Documented stable phlebotomy for ≥ 6 months
  • Screening hemoglobin >11.5 g/dL
  • Documented evidence of prior serum ferritin ≥500 ng/mL
  • Serum ferritin >50 ng/mL and <300 ng/mL at screening

Exclusion Criteria:

  • Clinically meaningful laboratory abnormality
  • Receiving iron chelation therapy
  • Receiving erythrocytapheresis
  • Pregnant or lactating females
  • Infection requiring hospitalization or intravenous antimicrobial therapy, or opportunistic infection within 3 months of dosing; any infections requiring antimicrobial therapy within 4 weeks of dosing.
  • Serious or unstable medical or psychiatric condition that would prevent subject providing informed consent
  • Organ damage from iron overload
  • Primary or secondary immunodeficiency
  • Positive hepatitis B or hepatitis C or known human immunodeficiency virus infection
  • Known history of autoimmune/inflammatory diseases
  • Any surgical procedures requiring general anesthesia within 1 month prior to screening or planned surgery during study
  • History of invasive malignancies within last 2 years, except non-malignant skin cancer and local cured prostrate cancer, cervical cancer, or ductal carcinoma in situ
  • Receipt of an investigational agent within 30 days of screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04202965

Layout table for location contacts
Contact: Study Director 1-888-899-1543

Layout table for location information
United States, Florida
Protagonist Investigational Site Not yet recruiting
Jacksonville, Florida, United States, 32224
Contact    888-899-1543   
United States, Maryland
Protagonist Investigational Site Not yet recruiting
Bethesda, Maryland, United States, 20817
Contact    888-899-1543   
United States, New York
Protagonist Investigational Site Recruiting
Port Jefferson Station, New York, United States, 11776
United States, Pennsylvania
Protagonist Investigational Site Recruiting
Philadelphia, Pennsylvania, United States, 19107
Canada, Nova Scotia
Protagonist Investigational Site Not yet recruiting
Halifax, Nova Scotia, Canada
Contact: Protagonist Therapeutics, Inc.    1-888-899-1543   
Sponsors and Collaborators
Protagonist Therapeutics

Layout table for additonal information
Responsible Party: Protagonist Therapeutics Identifier: NCT04202965    
Other Study ID Numbers: PTG-300-06
First Posted: December 18, 2019    Key Record Dates
Last Update Posted: December 18, 2019
Last Verified: December 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Metal Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Iron Overload
Iron Metabolism Disorders
Metabolic Diseases